Treatment alternatives for Mycobacterium kansasii.
Mycobacterium kansasii was administered intravenously to congenitally athymic (nude) mice. Beginning 1 week later, rifapentine, azithromycin, ethambutol or combined therapy was initiated orally. All three drugs were highly active individually. Although there was no evidence of antagonism, combined therapy was not more effective than either component used alone.
Department of Medicine, University of Texas Health Science Center, San Antonio, TX 78284, USA. graybill@uthscsa.edu
J R
JR
Graybill
R
R
Bocanegra
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D017963:Azithromycin / Q000008:administration & dosage / Q000627:therapeutic use*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000008:administration & dosage / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D009165:Mycobacterium Infections, Nontuberculous / Q000188:drug therapy* / Q000382:microbiology; D019909:Mycobacterium kansasii / Q000502:physiology; D012293:Rifampin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D016019:Survival Analysis
D000900:Anti-Bacterial Agents; D017963:Azithromycin; D004977:Ethambutol; D012293:Rifampin; C018421:rifapentine